Astute Medical Logo
Innovative biomarkers.  Smarter healthcare.


Educational sessions at AACN NTI 2017 to highlight shift from AKI diagnosis to prevention

SAN DIEGO – May 18, 2017 – Astute Medical, Inc., developer of biomarkers for better healthcare, today announced it will conduct educational sessions highlighting advances in the area of acute kidney injury (AKI) risk assessment at the American Association of Critical Care Nurses NTI 2017 in Houston May 22-25. The presentations will highlight how biomarkers measured by Astute Medical’s NephroCheck® Test can be used for risk assessment of AKI, shattering the myth that AKI is an unavoidable condition for many critically ill patients.

About half of the more than 5 million people admitted to intensive care units (ICU) in U.S. hospitals each year develop AKI,1 a potentially deadly condition that can progress for hours to days without symptoms.2 Clinicians encounter many dilemmas as they seek to risk assess critically ill patients and determine optimal therapies.2 Chief among these is overcoming the current limitations of standard-of-care kidney tests, which elevate only after damage has occurred and are compromised diagnostically in many types of patients.3

The NephroCheck® Test measures TIMP-2 and IGFBP-7, two biomarkers that have been associated with kidney stress indicative of AKI risk.4 Critical care nurses, who provide round-theclock care to these patients, can play a key role in earlier identification of those at risk of developing moderate to severe AKI. With early knowledge of AKI risk, the patient’s treatment can be tailored to mitigate risk.

During the NTI sessions, Astute Medical faculty will review the pathophysiology, etiology and epidemiology of AKI, as well as current definitions and classifications of the condition. They will also discuss the importance of [TIMP-2]x[IGFBP-7] as a tool for risk-assessment of AKI, and the role these biomarkers can play in the effort to prevent or mitigate the effects of AKI.

“Critical care nurses can be the patient’s first line of defense against AKI, so it’s crucial that they learn about this new tool, and see for themselves how this test can help them work smarter and faster to improve patient care,” said Tara Sanders, MSN, MA, APRN, ACNP-BC, a nurse practitioner in Dallas. “Historically we’ve been reactive to AKI, but by utilizing the NephroCheck® Test the critical care team can become proactive instead. The NephroCheck® Test is a great example of the new technology and cutting-edge science that nurses seek to learn about at the NTI,” Sanders said.

The American Association of Critical Care Nurses NTI attendees can learn more about the NephroCheck® Test at Astute Medical’s exhibition booth #4716.

Details of Astute Medical’s presentations follow:

Title: Shattering the Myth that AKI is Unavoidable: Shifting the Paradigm from Diagnosis to Prevention
Speakers: Teddie Proctor, BSN, RN; Elisha Lowe, MBA, RN; and Toni Rodriguez, BSN, RN
Dates and Times: Tuesday May 23 – 11:30 a.m. and 1:45 p.m.
                              Wednesday May 24 –11:30 a.m. and 1:45 p.m.
                              Thursday May 25 – 10:15 a.m.
Preregistration is not required.

Important Information About The NephroCheck® Test
The NephroCheck® Test System is intended to be used in conjunction with clinical evaluation in patients who currently have or have had within the past 24 hours acute cardiovascular and or respiratory compromise and are intensive care unit (ICU) patients as an aid in the risk assessment for moderate or severe AKI within 12 hours of patient assessment. The NephroCheck® Test System is intended to be used in patients 21 years of age or older.

Astute Medical’s NephroCheck® Test received 510(k)-clearance through the FDA’s de novo classification. The test is CE-marked and available in Europe.

For additional information visit

About Astute Medical, Inc. Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests.

The Company’s focus is community- and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. Astute Medical’s current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis.

Astute Medical is a founding corporate partner of 0by25, a human rights initiative aimed at eliminating preventable and treatable deaths from AKI worldwide by 2025.

For additional information, please visit


Astute Medical®, the AM logo, Astute140®NephroCheck®, the NephroCheck® logo, and AKIRisk® are registered trademarks of Astute Medical, Inc. in the United States. For information regarding trademarks and other intellectual property applicable to this product, including international trademarks, please see PN0646 Rev A 2017/05/12


Nadine Padilla
LawPadilla Communications
+1 (619) 507-9306


1Mandelbaum T, Scott DJ, Lee J, et al. Outcome of critically ill patients with acute kidney injury using the AKIN criteria. Crit Care Med. 2011;39(12):2659-2664.

2Ronco C, Ricci Z. The concept of risk and the value of novel markers of acute kidney injury. Crit Care. 2013;17:117-118.

3McCullough PA et al. Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference. Contrib Nephrol. 2013;182:13-29.

4Kellum JA, Chawla LS. Cell-cycle arrest and acute kidney injury: the light and dark sides. Nephrol Dial Transplant. (2015) 0: 1–7doi: 10.1093/ndt/gfv130.


©2019 Astute Medical, Inc. Astute Medical®, the AM logo, Astute140®NephroCheck®, the NephroCheck® logo, and AKIRisk® are registered trademarks of Astute Medical, Inc. in the United States. For information regarding trademarks and other intellectual property applicable to this product, including international trademarks, please see